Cargando…
CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer
BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to ca...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656391/ https://www.ncbi.nlm.nih.gov/pubmed/33209432 http://dx.doi.org/10.21037/jtd-20-2666 |
_version_ | 1783608373041692672 |
---|---|
author | Yang, Dong-Yong Lin, Yan-Ping Xue, Cheng Fan, Ji-Min Wang, Yi Cai, Chi Song, Duan-Hong Zeng, Yi-Ming |
author_facet | Yang, Dong-Yong Lin, Yan-Ping Xue, Cheng Fan, Ji-Min Wang, Yi Cai, Chi Song, Duan-Hong Zeng, Yi-Ming |
author_sort | Yang, Dong-Yong |
collection | PubMed |
description | BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to calculate the therapeutic dose amount of particles implanted, and the spacing and distribution of seeds in the target area and adjacent tissues. Under the guidance of CT, 20–55 particles were implanted at each site, with the total number of radioactive particles being 226, the particle spacing being 0.5–1.0 cm, and the implantation being performed in accordance with the principle of uniform implantation. The patients were each followed up with repeated pulmonary CT scans at 1, 3, 6, 12, 18, 24, 30 and 36 months after the procedure. In accordance with the response evaluation criteria in solid tumors (RECIST), the following definitions for responses were used: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD). RESULTS: There were 2 CRs and 4 PRs one month after procedure; six patients were followed up 3 months after procedure, including 2 CRs and 4 PRs; one patient was lost in follow-up, and 5 patients were followed up 6 months after procedure, including 3 CRs and 2 PRs; five patients were followed up 12 months after procedure, including 3 CRs, 1 PR and 1 PD. The single PD patient was again given CT-guided implantation of (125)I radioactive particles for the treatment of recurrent lesions. The pulmonary CT was repeated 6 months after procedure, and the response was evaluated as SD. Four patients were followed up 18 months after procedure, including 3 CRs and 1 PR; one patient was lost in follow-up and 3 patients were followed up 24 months after the procedure with the response being evaluated as CR for all of them; one patient was followed up 36 months after procedure, and the response was evaluated as PD. During the follow-up, no serious complications occurred in any of the patients. CONCLUSIONS: The preliminary clinical observation showed that (125)I radioactive particle implantation was a safe, reliable and effective therapeutic method for early lung cancer. |
format | Online Article Text |
id | pubmed-7656391 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-76563912020-11-17 CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer Yang, Dong-Yong Lin, Yan-Ping Xue, Cheng Fan, Ji-Min Wang, Yi Cai, Chi Song, Duan-Hong Zeng, Yi-Ming J Thorac Dis Original Article BACKGROUND: To analyze the efficacy of computed tomography (CT)-guided implantation of (125)I radioactive particles in treatment of early lung cancer. METHODS: Six patients were analyzed, including 4 squamous cell carcinoma, 1 adenocarcinoma, and 1 small cell lung cancer. TPS software was used to calculate the therapeutic dose amount of particles implanted, and the spacing and distribution of seeds in the target area and adjacent tissues. Under the guidance of CT, 20–55 particles were implanted at each site, with the total number of radioactive particles being 226, the particle spacing being 0.5–1.0 cm, and the implantation being performed in accordance with the principle of uniform implantation. The patients were each followed up with repeated pulmonary CT scans at 1, 3, 6, 12, 18, 24, 30 and 36 months after the procedure. In accordance with the response evaluation criteria in solid tumors (RECIST), the following definitions for responses were used: complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD). RESULTS: There were 2 CRs and 4 PRs one month after procedure; six patients were followed up 3 months after procedure, including 2 CRs and 4 PRs; one patient was lost in follow-up, and 5 patients were followed up 6 months after procedure, including 3 CRs and 2 PRs; five patients were followed up 12 months after procedure, including 3 CRs, 1 PR and 1 PD. The single PD patient was again given CT-guided implantation of (125)I radioactive particles for the treatment of recurrent lesions. The pulmonary CT was repeated 6 months after procedure, and the response was evaluated as SD. Four patients were followed up 18 months after procedure, including 3 CRs and 1 PR; one patient was lost in follow-up and 3 patients were followed up 24 months after the procedure with the response being evaluated as CR for all of them; one patient was followed up 36 months after procedure, and the response was evaluated as PD. During the follow-up, no serious complications occurred in any of the patients. CONCLUSIONS: The preliminary clinical observation showed that (125)I radioactive particle implantation was a safe, reliable and effective therapeutic method for early lung cancer. AME Publishing Company 2020-10 /pmc/articles/PMC7656391/ /pubmed/33209432 http://dx.doi.org/10.21037/jtd-20-2666 Text en 2020 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Yang, Dong-Yong Lin, Yan-Ping Xue, Cheng Fan, Ji-Min Wang, Yi Cai, Chi Song, Duan-Hong Zeng, Yi-Ming CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title | CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title_full | CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title_fullStr | CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title_full_unstemmed | CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title_short | CT-guided percutaneous implantation of (125)I particles in treatment of early lung cancer |
title_sort | ct-guided percutaneous implantation of (125)i particles in treatment of early lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656391/ https://www.ncbi.nlm.nih.gov/pubmed/33209432 http://dx.doi.org/10.21037/jtd-20-2666 |
work_keys_str_mv | AT yangdongyong ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT linyanping ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT xuecheng ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT fanjimin ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT wangyi ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT caichi ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT songduanhong ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer AT zengyiming ctguidedpercutaneousimplantationof125iparticlesintreatmentofearlylungcancer |